...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer: A Journal of the American Cancer Society >Twenty Years Post-NIH Revitalization Act: Enhancing Minority Participation in Clinical Trials (EMPaCT): Laying the Groundwork for Improving Minority Clinical Trial Accrual Renewing the Case for Enhancing Minority Participation in Cancer Clinical Trials
【24h】

Twenty Years Post-NIH Revitalization Act: Enhancing Minority Participation in Clinical Trials (EMPaCT): Laying the Groundwork for Improving Minority Clinical Trial Accrual Renewing the Case for Enhancing Minority Participation in Cancer Clinical Trials

机译：美国国立卫生研究院（NIH）振兴法案颁布二十周年：增强少数族裔对临床试验的参与（EMPaCT）：为改善少数族裔临床试验的基础打下基础，为进一步增加少数族裔参与癌症临床试验的案件奠定基础

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: The National Institutes of Health (NIH) Revitalization Act of 1993 mandated the appropriate inclusion of minorities in alt N!H-funded research. Twenty years after this act, the proportion of minority patients enrolled in cancer clinical trials remains persistently low. Clinical trials are vehicles for the development and evaluation of therapeutic and preventive agents under scientifically rigorous conditions. Without representation in trials, it is projected that disparities in the cancer burden for minorities will increase. METHODS: For this review article, the authors counted the frequency with which minorities were the primary focus of National Cancer Institute-sponsored clinical trials, examined citations from the PubMed database focusing on the search terms "NIH Revitalization Act of 1993" and "enhancing minority accrual to cancer clinical trials," and supplemented the review with their expertise in NIH-funded research related to minority accrual in cancer clinical trials. RESULTS: The reporting and analyses of data based on minorities in clinical trials remain inadequate. Less than 2% of the National Cancer Institute's clinical trials focus on any racial/minority population as their primary emphasis. The current review of the literature indicated that the percentage of authors who reported their study sample by race/ethnicity ranged from 1.5% to 58%, and only 20% of the randomized controlled studies published in a high-impact oncology journal reported analyzing results by race/ethnicity. Proportionately greater population increases in minorities, accompanied by their persistent and disproportionate cancer burden, reinforce the need for their greater representation in clinical trials. CONCLUSIONS: Renewing the emphasis for minority participation in clinical trials is warranted. Policy changes are recommended.
机译：背景：1993年的美国国立卫生研究院（NIH）振兴法案要求在N！H资助的替代研究中适当纳入少数群体。该法案颁布二十年后，参加癌症临床试验的少数患者的比例一直持续偏低。临床试验是在科学严格条件下开发和评估治疗剂和预防剂的工具。如果没有在临床试验中的代表，预计少数群体的癌症负担差异将会增加。方法：在这篇评论文章中，作者计算了少数群体成为美国国家癌症研究所资助的临床试验的主要重点的频率，检查了PubMed数据库中的引文，重点是搜索词“ 1993年NIH振兴法案”和“增强少数群体”癌症临床试验的应计项目”，并以其在NIH资助的与癌症临床试验中的少数应计项目相关的研究中的专业知识作为补充。结果：在临床试验中基于少数群体的数据报告和分析仍然不足。美国国家癌症研究所不到2％的临床试验将重点放在任何种族/少数民族人口上。当前对文献的评论表明，按种族/民族报告其研究样本的作者百分比范围为1.5％至58％，在高影响力肿瘤学杂志上发表的随机对照研究中，只有20％报告了通过种族/民族。少数民族中人口的增加成比例地增加，同时伴随着他们持续和不成比例的癌症负担，这增加了他们在临床试验中的代表性的需求。结论：有必要重新强调少数群体参与临床试验。建议更改策略。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号